For a male patient with prior stroke, how long should he remain on low‑dose aspirin for secondary prevention?

Duration of Aspirin Therapy After Stroke

For a male patient with prior stroke, aspirin should be continued indefinitely for secondary prevention—this is lifelong therapy that should not be stopped. 1

Core Recommendation

Antiplatelet therapy with aspirin (50-325 mg daily) is indicated for continuous, long-term secondary prevention of recurrent ischemic stroke in patients with noncardioembolic stroke 1. The 2021 AHA/ASA guidelines establish this as a Class 1, Level A recommendation, meaning there is strong evidence supporting indefinite continuation of antiplatelet therapy.

Key Treatment Phases

Initial Period (First 21-90 Days)

• If the stroke was minor (NIHSS ≤3) or high-risk TIA, dual antiplatelet therapy (DAPT) with aspirin plus clopidogrel should have been initiated within 12-24 hours and continued for 21-90 days 1
• After this initial DAPT period, transition to single antiplatelet therapy (SAPT)

Long-Term Maintenance (After 90 Days)

• Continue aspirin monotherapy indefinitely 1
• The typical dose is 81-325 mg daily, with 81 mg being most commonly used for long-term secondary prevention
• There is no predetermined endpoint for stopping aspirin therapy

Critical Evidence on Discontinuation Risks

Stopping aspirin significantly increases stroke risk. Research demonstrates that discontinuing low-dose aspirin is associated with a 40% increased risk of ischemic stroke or TIA within 31-180 days of stopping 2. The mean time to acute cerebrovascular events after aspirin withdrawal is 14.3 days 3.

Additionally, discontinuation of aspirin after hemorrhagic stroke was associated with decreased survival (HR 1.54) 4, suggesting that even in high-risk bleeding scenarios, the vascular protective benefits often outweigh risks when carefully considered.

Important Caveats

When DAPT Should NOT Continue Beyond 90 Days

• Long-term DAPT (aspirin plus clopidogrel) beyond 90 days is associated with excess hemorrhage risk, including intracranial hemorrhage, without additional stroke prevention benefit 1
• The bleeding risk begins to outweigh benefits as early as 21-90 days with DAPT 1

Exceptions Requiring Reevaluation

• Hemorrhagic transformation or major bleeding: While aspirin increases bleeding complications by a factor of 1.5, it typically does not increase severity except in intracranial surgery contexts 3
• Planned surgical procedures: Weigh cardiovascular risks (which manifest within 8-14 days of stopping) against procedure-specific bleeding risks 3
• Intracranial hemorrhage: Even after hemorrhagic stroke, low-dose aspirin use was associated with 32% improved survival, particularly in patients who were on antithrombotic therapy before the hemorrhage 4

Monitoring Considerations

• Patient adherence is the most common reason for discontinuation 2
• Emphasize to patients that this is lifelong therapy
• If already on aspirin at time of recurrent stroke, the effectiveness of increasing dose or switching agents is not well established 1

Bottom Line Algorithm

1. Days 0-90: DAPT if minor stroke/high-risk TIA, otherwise SAPT
2. After 90 days through end of life: Aspirin monotherapy (typically 81 mg daily)
3. Never stop without compelling reason: Discontinuation increases stroke risk by 40% within months
4. If bleeding occurs: Reassess risk-benefit, but recognize that even post-hemorrhagic stroke patients may benefit from aspirin continuation

The answer to "how long" is straightforward: indefinitely, unless a specific contraindication develops that outweighs the substantial cardiovascular protection aspirin provides.